[EN] GLYT2 MODULATORS<br/>[FR] MODULATEURS DU GLYT2
申请人:JANSSEN PHARMACEUTICA NV
公开号:WO2005044810A1
公开(公告)日:2005-05-19
α-, β-, and Ϝ-amino acid derivatives of formula I are disclosed as selective GlyT2 inhibitors for the treatment of central nervous system (CNS) conditions such as muscle spasticity, tinnitus, epilepsy and neuropathic pain. Formula I
Certain α-, β-, and γ-amino acid derivatives are disclosed as selective GlyT2 inhibitors for the treatment of central nervous system (CNS) conditions such as muscle spasticity, tinnitus, epilepsy and neuropathic pain.
Novel glycine transporter type-2 reuptake inhibitors. Part 2: β- and γ-amino acid derivatives
作者:Ronald L Wolin、Alejandro Santillán、Tristin Barclay、Liu Tang、Hariharan Venkatesan、Sandy Wilson、Doo Hyun Lee、Timothy W Lovenberg
DOI:10.1016/j.bmc.2004.05.043
日期:2004.8
Several beta- and gamma-amino acid derivatives were prepared as glycine transport inhibitors and their ability to block the uptake of [C-14]-glycine in COS7 cells transfected with human glycine transporter-2 (hGlyT-2) were evaluated. A range of lipophilic side chains were tolerated in the beta-amino acid series (i.e., Ph, CH2Ph, CH(CH3)(2), and CH2CH(CH3)(2)). In the gamma-amino acid series, minimal differences in potency were observed between the alpha, beta-unsaturated analogs and the corresponding saturated derivatives. In both series, a 4-biphenyl or 4-phenoxyphenyl substituent appended to the urea or cyanogunaidine moiety was necessary for in vitro activity. (C) 2004 Elsevier Ltd. All rights reserved.